920-106 real questions | Pass4sure 920-106 real questions |

Pass4sure 920-106 dumps | 920-106 actual questions |


Study lead Prepared by Nortel Dumps Experts 920-106 Dumps and actual Questions

100% actual Questions - Exam Pass Guarantee with high Marks - Just Memorize the Answers

920-106 exam Dumps Source : NNCSS SYMPOSIUM muster CENTER

Test Code : 920-106
Test cognomen : NNCSS SYMPOSIUM muster CENTER
Vendor cognomen : Nortel
real questions : 90 actual Questions

Nice to hear that actual test questions of 920-106 exam are available.
I own earned higher scores in 920-106 certification with the serve of quite inexpensive products. I got 920-106 exam engine to regain rid of hard standards of this certification. I had sold 920-106 exam braindump to own splendid grades within the certification. It conclude up pinnacle altenative due to the fact the ones merchandise are designed in line with my brain-set. It helped me to regain read in fifteen days and after this brief time I had scored specific with the serve of these practical merchandise consequently im writing to mention manner to complete of you in your top class services.

it's miles unbelieveable, but 920-106 present day dumps are availabe privilege here.
Today I am very ecstatic because I own got a very high score in my 920-106 exam. I couldnt reflect I would breathe able to upshot it but this made me reflect otherwise. The online educators are doing their job very well and I salute them for their dedication and devotion.

No squander of time on searhching internet! institute exact source of 920-106 actual questions .
I moreover had a splendid revel in with this training set, which led me to passing the 920-106 exam with over ninety eight%. The questions are actual and valid, and the exam simulator is a tremendous/guidance device, despite the fact that you are no longer planning on taking the exam and sincerely want to expand your horizons and enlarge your knowledge. i own given mine to a pal, who also works on this situation but clearly received her CCNA. What I imply is its a splendid reading device for absolutely everyone. And if you blueprint to elect the 920-106 exam, this is a stairway to achievement :)

Take gross gain state-of-the-art 920-106 actual examination actual questions and regain licensed.
Going thru actual questions has advance to breathe a addiction whilst exam 920-106 comes. And with test springing up in pretty a gross lot 6 days actual questions changed into getting extra critical. But with subjects I want a few reference manual to slip occasionally in order that i would regain better help. Manner to their actual questions that made it complete simple to regain the subjectsinterior your head easily which would in any other case might breathe no longer viable. And its far complete because of products that I controlled to gain 980 in my exam. Thats the highest marks in my beauty.

simply try those modern-day dumps and achievement is yours.
Knowing thoroughly about my time constraint, commenced out trying to find an cleanly pass out before the 920-106 exam. After a protracted searh, placed the question and answers via pass of which without a doubt made my day. Offering complete probably questions with their quick and pointed solutions helped hold near subjects in a brief time and felt ecstatic to secure actual marks inside the exam. The materials also are cleanly to memorise. I am inspired and satiated with my results.

much less effort, fanciful expertise, assured success.
I was 2 weeks short of my 920-106 exam and my preparation was not complete done as my 920-106 books got burnt in fire incident at my place. complete I thought at that time was to quit the option of giving the paper as I didnt own any resource to prepare from. Then I opted for and I still am in a condition of shock that I cleared my 920-106 exam. With the free demo of, I was able to grasp things easily.

Did you attempted this outstanding supply cutting-edge 920-106 dumps. works! I passed this exam ultimate drop and at that time over 90% of the questions were absolutely valid. They are highly likely to still breathe convincing as cares to update their materials frequently. is a noteworthy organization which has helped me more than once. I am a regular, so hoping for discount for my next bundle!

Is there 920-106 exam current sayllabus?
I just bought this 920-106 braindump, as soon as I heard that has the updates. Its genuine, they own covered complete current areas, and the exam appears very fresh. Given the current update, their rotate round time and serve is top notch.

actual 920-106 questions and accurate solutions! It warrant the charge.
because of 920-106 certificates you purchased many possibilities for security specialists development on your career. I wanted to development my vocation in information protection and desired to grow to breathe certified as a 920-106. if so I decided to elect serve from and commenced my 920-106 exam training through 920-106 exam cram. 920-106 exam cram made 920-106 certificates research smooth to me and helped me to obtain my desires effortlessly. Now im able to negate without hesitation, without this internet site I in no pass passed my 920-106 exam in first strive.

How much does it cost 920-106 qustions bank with actual dumps
Yes, the questions and answers could breathe very useful and i hint it to complete people who wants to elect those checks. Congrats on a process nicely understanding out and completed. I cleared my 920-106 tests.


VoIP certification tracks - Nortel's advocate certifications | actual Questions and Pass4sure dumps

As outlined in a outdated tip, companies are implementing IP telephony more commonly on their facts infrastructures. The accelerated deployment has created a exigency for certified IP telephony engineers to deliver proven, most beneficial-of-breed expertise.

The IP telephony certifications Nortel at present presents are divided into four classes: lead specialist, Design expert, advocate skilled, and Design skilled. This tip discusses the Nortel advocate music.

assist specialist

The lead professional certifications are intended to demonstrate an individual's means to redeem into effect, operate, and troubleshoot a Nortel Networks IP Telephony answer. The advocate expert certification reflects a candidate with three to six months of event that can deal with pursuits technical issues of a common Nortel IP Telephony answer.

NNCSS - VoIP Succession BCM 3.0

This certification checks the skill to redeem into effect, function, and troubleshoot the company Communications supervisor three.0. This certification covers hardware, beginning-up, facts and voice networking, applications, and troubleshooting the BCM. To flood the certification, two checks exigency to breathe successfully completed: know-how requisites and Protocols for IP Telephony options, and Succession BCM three.0. The technology necessities and Protocols for IP Telephony solutions exam is an silhouette of convergence technologies.

NNCSS - CallPilot Rls. 2.0

This certification exams the means to redeem in force, function, and troubleshoot the VoIP CallPilot 2.0. This certification covers hardware, administration, interoperability with Meridian 1 switches, and security of a lone website CallPilot system. To flood the certification, two tests must breathe successfully achieved: Meridian Database and CallPilot 2.0.

NNCSS - Symposium cognomen middle Server or Symposium cognomen heart Server installation and protection

These two certifications watch at various the skill to implement, operate, and troubleshoot the Symposium cognomen heart Server. both certifications cover hardware, utility installing, administration, and protection of Symposium muster core Server 4.2, Symposium web client 4.0, and Symposium categorical three.0. besides the fact that children, the Symposium muster heart Server certification also tests the architecture, customized configuration and integration of the server. To pass either of those certifications, one exam own to breathe efficiently achieved: Symposium muster heart or Symposium muster core installation and maintenance, respectively.

NNCSS - Symposium muster heart TAPI/Agent or muster heart TAPI/Agent installing and preservation

These two certifications verify the talent to redeem in force, operate, and troubleshoot the Symposium cognomen heart TAPI/Agent. each certifications cover hardware, software setting up, administration, and renovation of Symposium TAPI 2.three and Symposium Agent 2.three. however, the Symposium muster heart TAPI/Agent certification also checks the structure, integration, and custom configuration of the TAPI/Agent. To slip both of those certifications, one examination must breathe efficaciously completed: Symposium muster middle TAPI/Agent or Symposium muster core TAPI/Agent Inst/leading, respectively.

NNCSS - Symposium specific muster core or Symposium express cognomen middle installation and renovation

These certifications examine the talent to enforce, function, and troubleshoot the Symposium specific cognomen middle. both certifications cowl hardware, utility installing, administration, and protection of Symposium express muster heart four.2. despite the fact, the Symposium categorical muster heart certification also checks the structure and integration of the cognomen middle. To flood both of the certifications, one examination ought to breathe efficiently accomplished: Symposium categorical muster heart or Symposium categorical muster heart Inst and Maint respectively.

NNCSS - VoIP Multimedia communique Server (MCS) 5100 2.0

This certification tests the capability to implement, operate, and troubleshoot the VoIP Multimedia verbal exchange Server (MCS) 5100 2.0. This certification covers setting up of the hardware and application, configuration, preservation, and administration of the Multimedia communication Server (MCS) 5100 2.0. To slip the certification, two assessments must breathe efficiently achieved: expertise standards and Protocols for IP Telephony solutions, and VoIP Multimedia verbal exchange Server (MCS) 5100 2.0. The know-how specifications and Protocols for IP Telephony options examination is an overview of convergence technologies.

NNCSS - VoIP Succession 1000/1000M Rls. 3.0 DB Administrator

This certification checks the potential to preserve and troubleshoot the VoIP Succession 1000/1000M Rls. three.0 DB Administrator. This certification covers the structure, configuration, upkeep, and administration of the Meridian 1, Succession one thousand Rls. 3.0, and Succession 1000M Rls. 3.0 the utilize of simple Alternate Route alternative (BARS) and network Alternate Route selection (NARS). To circulate the certification, two tests exigency to breathe successfully completed: expertise requisites and Protocols for IP Telephony solutions, and Succession a thousand/1000M Rls. 3.0 DB Administrator.

NNCSS - VoIP Succession one thousand/1000M Rls. three.0 setting up and upkeep

This certification exams the capacity to set up, configure, and maintain the VoIP Succession 1000/1000M Rls. 3.0. This certification covers the setting up, structure, configuration, preservation, and administration of the Meridian 1, Succession one thousand Rls. 3.0, and Succession 1000M Rls. three.0, cyber web Telephones i2xxx, and Optivity Telephony manager (OTM) 2.1. To circulate the certification, three tests must breathe efficaciously achieved: know-how specifications and Protocols for IP Telephony solutions, and Succession 1000/1000M Rls. 3.0 for Technicians, and Succession 1000/1000M Rls. three.0.

support professional

The aid expert certifications build on the specialist's expertise by demonstrating their talent to redeem in force, operate, and troubleshoot an advanced Nortel Networks IP Telephony solution. The serve professional certifications reflect a candidate with six to twelve months of fingers-on journey with the means to lead or aid intermediate-level personnel to preserve complex Nortel IP Telephony solutions.

NNCSE - CallPilot 2.0 Unified Messaging options

This certification assessments the talent to enforce, operate, troubleshoot and optimize the VoIP CallPilot Unified Messaging solution 2.0. This certification covers the installing, administration, interoperability, security, help techniques and feature usage for a multi web site CallPilot system. To pass the certification, the candidate exigency to first gain their NNCSS - CallPilot Rls. 2.0. consequently, the CallPilot 2.0 Unified Messaging solutions own to breathe efficaciously completed to acquire this certification.

NNCSE - Contact middle

This certification checks the potential to redeem into effect, operate, troubleshoot and optimize the Contact heart products. This certification covers the candidate's capabilities on the Symposium muster middle Server (SCCS)/Symposium express muster middle/Symposium net customer, Symposium TAPI service provider (TAPI SP), Symposium Agent, and the Symposium net heart Portal. To circulate the certification, the candidate ought to first acquire their NNCSS - Symposium cognomen heart Server and the NNCSS - Symposium muster heart TAPI/Agent certification. in consequence, the Contact middle examination own to breathe correctly accomplished to gleam this certification.

NNCSE - IP Convergence Succession 1000/1000M Rls. 3.0

This certification checks the means to deploy, configure, retain, and optimize the VoIP Succession 1000/1000M Rls. 3.0. This certification covers the configuration, succession department office (BO), remote workplace, operation, and Meridian 1 to Succession 1000M three.0 migration procedures for the Succession a thousand/1000M Rls. 3.0, web Telephones i2xxx, faraway office 91xx, and Optivity Telephony manager (OTM) 2.1. To pass the certification, the candidate own to first obtain their NNCSS - VoIP Succession CSE 1000 Rls. 2.0 or the VoIP Succession 1000/1000M Rls. 3.0 installing & maintenance certification. as a result, an extra greater problematic version of the Succession 1000/1000M Rls. three.0 examination should breathe efficaciously achieved to achieve this certification.

within the IT trade, certifications are a manner to validate an individual's handicap within a exact area. The above Nortel IP Telephony certifications are probably the most materiel that may array the capabilities of an IP Telephony assist professional. These certifications couldn't substitute years of industry event, however they upshot deliver the foundation to advocate and maneuver Nortel Voice over IP solutions.

The next tip will talk about Nortel's Design IP Telephony certification music.

Richard Parsons (CCIE#5719) is a manager of skilled capabilities for Callisma Inc., a totally owned subsidiary of SBC. He has constructed a superb groundwork in networking ideas, advanced troubleshooting, and monitoring in areas akin to optical, ATM, VoIP, routed, routing, and storage infrastructures. rich resides in Atlanta GA, and is a graduate of Clemson institution. His tradition includes senior and predominant consulting positions at international network features, Lucent, and Callisma.

Bel Fuse (BELFB) this drop 2018 revenue conference muster Transcript | actual Questions and Pass4sure dumps

Logo of jester cap with thought bubble with words 'Fool Transcripts' below it

picture source: The Motley fool.

Bel Fuse (NASDAQ:BELFB)this autumn 2018 earnings convention CallFeb. 21, 2019 11:00 a.m. ET

  • organized Remarks
  • Questions and solutions
  • name participants
  • organized Remarks:


    first rate day, and welcome to the Bel Fuse Inc. fourth quarter and full-year 2018 results conference name. modern day convention is being recorded. at present, i want to demonstrate the convention over to Mr.

    Dan Bernstein, president and chief executive officer. gladden Go ahead, sir.

    Dan Bernstein -- President and Chief govt Officer

    thank you, Allison. becoming a member of me on the cognomen nowadays is Craig Brosious, their vice president of Finance; and Lynn Hutkin, their director of fiscal reporting. earlier than they start the call, i might enjoy to seekinformationfrom Lynn to slip over the secure harbor remark. Lynn?

    Lynn Hutkin -- Director of fiscal Reporting

    thank you, Dan. decent morning, everybody. before they start, i might enjoy to read here secure harbor statement. except for historic suggestions contained on this call, the concerns discussed on this cognomen corresponding to statements related to expected multiply from the business's distribution channel, the results of the ERP system implementation and different high-quality commerce and multiply traits are forward-searching statements as described below the inner most Securities Litigation Reform Act of 1995 that involves dangers and uncertainties.

    exact effects could fluctuate materially from those projections. among the factors that might trigger genuine consequences to vary materially from such statements are: the market considerations facing their purchasers; the continuing viability of sectors that matter on their products; the outcomes of company and economic conditions; difficulties associated with integrating currently obtained agencies; means and supply constraints or difficulties; product building, commercialization or technological difficulties; the regulatory trade ambiance; dangers associated with foreign currency; uncertainties associated with prison proceedings; the market's acceptance of the business's current items and competitive responses to these current products; the influence of alterations to U.S. change and tariff policies; and the risk elements exact sometimes within the company's SEC stories. In simple of the hazards and uncertainties, there may also breathe no assurance that any forward-looking statement will, in fact, demonstrate to breathe proper.

    We undertake no obligation to update or revise any ahead-looking statements. They may additionally also talk about non-GAAP effects throughout this muster and reconciliations of their GAAP consequences to non-GAAP effects were protected in their liberate. And simply earlier than turning the cognomen back to Dan, I simply desired to supply each person a heads up that their EBITDA reconciliation table in their accustomed release became fallacious. there were errors in that desk and a brand current release is popping out.

    So gladden bounce that introductory desk. So it truly is the third table, which is on web page 7 of the liberate.

    Dan Bernstein -- President and Chief govt Officer

    thanks, Lynn. earlier than going throughout the financials, i want to provide a short update on how the companies did from an operational standpoint this quarter and what they notice going ahead. usual, we're very completely satisfied that they closed the 12 months with a different strong quarter, bringing their 2018 sales to $548 million, their larger revenue year for the understanding that 2015. extra importantly, their net income for the year of $21 million become the highest in over a decade.

    revenue complete the pass through the fourth quarter were $142.7 million, up 19% from the fourth quarter of 2017 with double-digit growth in each and every of the 3 leading product lines. Their backlog of orders remained mighty at $171.2 million at December 31, 2018, a ascend of 17% from a 12 months in the past. The enhance in backlog is also considered across every of their main product companies, which is a top-notch barometer for different future increase. and searching via at the full 12 months.

    Our Magnetic solutions neighborhood closed the 12 months with $24.4 million enhance in sales over 2017 stages led by high exact for their built-in connector modules that are used in next-technology switching functions. revenue of their signal Transformer items own been additionally potent privilege through 2018 as current courses with clinical and industrial purposes moved into full production. they now own also increased the presence of their magnetic items via their distribution channels, which add to the 12 months-over-12 months sales growth. The backlog of orders from magnetic items grew by pass of $9.7 million or 28% enhance for the understanding that the 2017 yr-end.

    Our Connectivity solutions neighborhood had yr-over-year revenue multiply of $sixteen.four million. Their Cinch enterprise expanded profits via $8.2 million compared to 2017 led via mighty exact for optical and copper products utilized in encryption, communication and threat detection radar applications. Their Stewart passive connectors additionally saw boost in income of $8.2 million from 2017 as better fiscal conditions in the structure commerce led to high exact for their premise wiring customs throughout the year. The Cinch and Stewart enterprise also profit from wonderful multiply in earnings through their distribution channel in 2018.

    average, the backlog of orders for their Connectivity products grew by using $7.8 million, or 16%, in view that 2017 12 months-conclusion stages. Their power options and insurance policy community had a turnaround yr as revenue boom of $15.8 million from 2017 led this community to its first 12 months of sales multiply when you account that 2015. with the exception of the consequences of their NPS divestiture, sales for this group were up $21 million or 14% from closing 12 months, pushed by pass of continued exact for their power supplies in diversity of information core functions. sales of their DC to DC and circuit insurance policy products also grew in 2018, offset by using a decline favorite for their custom modules.

    The backlog of their orders for their vigour solutions and insurance policy community is up $7.1 million or eleven% from 2017 yr-conclusion levels. From a profitability standpoint, overseas trade top-notch points and a top-notch adjustment draw the transition tax out to mitigate the larger labor and fabric charges that impacted their bottom line this yr. They proceed to hang pricing company as they drudgery through their higher cost stock on end. concerning the tariffs that had been implemented in 2018, they assay that about 10% of their consolidated annual revenues are at the flash impacted.

    At this element, the bulk of these charges own been handed along to their customers in the contour of invoice can charge. They proceed to monitor the situation carefully as they manner the tentative March 1 time restrict for the U.S. accomplishing a pretty top-notch cope with China in complete event extra increases on existing tariffs. typical, they wait cautiously confident with the continued income boom and profitabilities as they enter 2019.

    And with that, i would flip it over to Craig to dash in the course of the fiscal replace.

    Craig Brosious -- vice president of Finance

    Thanks, Dan. To supply a quick recap on income. revenue during the fourth quarter were $142.7 million. through geographic segment, North america earnings own been $70.3 million, Asia income were $49.1 million and Europe own been $23.3 million.

    with the aid of product neighborhood, Connectivity solutions income had been $46.four million, Magnetic solutions income were $forty eight.6 million and vigour options and insurance blueprint revenue were $47.7 million. uncouth profit margin expanded to 21.3% in the fourth quarter of 2018 as in comparison with 18.5% within the fourth quarter of 2017 as incremental earnings in 2018 ended in more suitable fastened can suffuse absorption offsetting larger labor expenses complete over the yr. moreover, their uncouth earnings margin complete through the fourth quarter of 2017 own been impacted through inventory-related costs totaling $2 million in connection with keeping their stock on the lower can suffuse or net realizable cost. Their selling, commonplace and administrative expenses were $22.2 million or 15.6% of income as in comparison with $21.1 million or 17.6% of income in the fourth quarter of 2017.

    while the multiply in SG&A costs complete the pass through the 2018 length $900,000 pertains to a decline in market cost of their COLI policies, which changed into in accordance with the simple inventory market recreation during the fourth quarter of 2018. they now own already began to peer this invert in 2019. different offsetting components that affected that the variance in the fourth-quarter durations had been better legal and expert charges of $800,000 offset by using a lessen in unhealthy debt cost of $500,000 and a discount in depreciation and amortization of $four hundred,000. On a go-ahead groundwork, they might foretell SG&A to dash between $20 million and $21 million per quarter within the near time period, barring any huge fluctuations in foreign currency echange.

    because of these factors, they generated earnings from operations of $8 million in the fourth quarter of 2018 as in comparison to $1 million within the fourth quarter of 2017. pastime expense changed into -- i'm sorry, $1.4 million in the fourth quarter of 2018, down $900,000 from the identical duration closing yr. in case you preserve in mind, they refinanced their credit agreement in the fourth quarter of 2017, which ended in an acceleration of deferred financing cost amortization of $1 million during the remaining year's fourth quarter. Their provision for profits taxes became $2.four million for the fourth quarter of 2018 compared to $19.2 million complete through final year's fourth quarter.

    the supply for revenue taxes privilege through the fourth quarter of 2018 was unfavorably impacted via taxes on international salary, the GILTI tax, partially offset by a abate within the U.S. tax cost from 35% to 21% in 2018. the availability for revenue taxes in 2017 era included an $18 million impact from the U.S. Tax Cuts and Jobs Act, which become enacted on December 22, 2017.

    profits per partake for category a common shares was $0.31 per partake in the fourth quarter of 2018 as compared with a loss of $1.sixty six per partake in the fourth quarter of 2017. earnings per partake for class B general shares was $0.33 per partake within the fourth quarter of 2018 as compared with the want of $1.seventy four per partake in the fourth quarter of 2017. On a non-GAAP groundwork, which excludes inescapable peculiar and different nonrecurring items, EPS for category A shares become $0.37 per partake in the fourth quarter of 2018 as compared with the loss of $0.09 per partake in the fourth quarter of 2017. On a non-GAAP groundwork, EPS for class B shares turned into $0.39 per partake in the fourth quarter of 2018 as in comparison with a want of $0.10 per partake within the fourth quarter of 2017.

    And now i would enjoy to Go through some stability sheet and cash circulation gadgets. Their money and cash equivalents balance at December 31, 2018, changed into $fifty three.9 million, a lessen of $15.4 million from December 31, 2017. privilege through 2018, they made payments of $9 million towards their Amazing debt steadiness. They also used cash for capital charges of $11.6 million, dividend funds of $3.3 million and hobby funds of $four.8 million.

    money owed receivable were $ninety one.9 million at December 31, 2018 as compared with $78.8 million at December 31, 2017. Days income striking own been 59 days at December 31, 2018, compared to 60 days at December 31, 2017. The boost in debts receivable stability changed into generally because of the bigger revenue volume within the fourth quarter of 2018 as compared to the fourth quarter of 2017. Inventories were $120.1 million at December 31, 2018, up $12.three million from December 31, 2017.

    In January of 2018, they adopted the current income cognizance regular, which hastens the timing during which they earnings become identified and the corresponding liberate of comprehensive items from their stock balance concerning items held at customer control hubs. except for the results of this adoption, their stock stability would own elevated by $23.4 million from December 31, 2017, essentially uncooked materials and work-in-growth in keeping with the enhance well-known for their products in 2018. accounts payable had been $fifty six.2 million at December 31, 2018, up $8.2 million from its degree at December 31, 2017 because of the raise in raw material purchases. Bel's total fanciful debt turned into reduced with the aid of $744,000 during the fourth quarter, bringing the balance down to $116 million as of December 31, 2018, aside from deferred financing cost.

    ebook cost per share, which is calculated as stockholders' equity divided by pass of their combined A and B classes of simple inventory impressive, become $14.39 per partake at December 31, 2018 as in comparison to $13.13 per partake at December 31, 2017. And now i want to demonstrate the cognomen returned to Dan and open the muster for questions.

    Dan Bernstein -- President and Chief government Officer

    yes. upshot they open up the exact questions, please, Allison? 

    Questions and answers:


    actually, sir. [Operator instructions] they are able to now elect their first question from Sean Hannan from Needham & enterprise. gladden Go ahead, sir.

    Sean Hannan -- Needham and enterprise -- Analyst

    yes. Thanks. respectable morning, everyone. Dan, i used to breathe looking to notice if I might seekinformationfrom you might provide us with a puny bit of detail across the phase.

    i upshot know you offered some on your prepared feedback. can you in complete probability regain into a bit bit extra specificity when it comes to how had been you emotion with each of these section nowadays and the actions they ramp privilege here within the first quarter and in '19. and perhaps how that may additionally own trade or could breathe different versus what you were expecting probably just a brace of months in the past? Any perception there could breathe very effective. Thanks.

    Dan Bernstein -- President and Chief govt Officer

    adequate. Of path, complete of their product businesses and complete of the subdivisions inside the product corporations, a majority, i would say, 80% of complete were very robust. they now own one community, is the Modular group and the DC to DC neighborhood out of Italy which own some tremendous clients that they misplaced, but that hasn't been the comfort to upshot with the market conditions simply on account of the situation with these clients. So ordinary everything has been, as you breathe awake of, extraordinarily fine.

    Going into this quarter and subsequent quarter, January become a very -- they saw a strong January, and once again, they suppose they upshot not notice any alterations within the first quarter. The handiest concerns that they upshot own is there are some IC businesses that are seeing some softening in the market and they upshot hear some rumblings that there may breathe too a lot inventory in the pipeline. but to this point it has not affected their revenue or backlog. So again, it's why I account we're a bit wonderful for the first quarter and for instance, I suppose near out after that.

    Sean Hannan -- Needham and company -- Analyst

    adequate. objective ample. Now as they look into the power neighborhood, it is definitely always a topic on each and every name. there's a gross lot that you've done when it comes to correcting the nice concerns from one of the vital acquisitions you've got taken on, there's a noteworthy deal you could own been doing to step-up executions, plenty that you own executed in incrementally successful current designs and into current programs some of which has been getting some momentum.

    and that i suppose you said that a bit bit earlier today. What extra may still they expect within the trajectory of these organizations? Is there the comfort within the history that's incrementally being labored down or is obtainable a bogey that might accelerate up the boom trajectory that you're now atmosphere into today? Or how should still they account about how this continue to enhance as a product section for you? Thanks.

    Dan Bernstein -- President and Chief govt Officer

    good enough. So the dash community, again, as they brought up over the ultimate two or three years, they dependence very strongly that has the best boom expertise for Bel from a accurate-line standpoint. On the power, they did own is after they acquired the company previous administration truly failed to heart of attention on pleasant and customer service. And it took us a very long time to exchange that; a, first change their manufacturing unit then exchange the client opinion, and over the ultimate 18 months, they now own complete their purchasers are back and believe Bel to breathe a power corporation.

    I feel two issues that they now own achieved that they now own changed these days. One became, I consider, as they own been so desperate for earnings, they took a shotgun approach and really redeem complete restrain on their R&D community without getting the ilk of effects that they would like. So what we've performed is, truly long past from much greater chosen manner of what consumers you exigency to deal with, how they fit into us and should they breathe long-time era shoppers? With that said, they are streamlining their R&D community because they will not own to Go with the southbound method, they comprehend what precisely engineers they deserve to lead these products as they circulate ahead. the key vicissitude now could breathe that they upshot own two or key key customers that may Go anywhere from $eight million to $12 million, $13 million.

    And once we're talking about statistics middle-category of customer, they upshot own gargantuan customer classification of valued clientele. again, those fluctuate very gargantuan from a earnings standpoint. once more, however, they upshot reflect that we've located ourselves much more within the market, and currently I feel they now own 90 NDA signed on high-effectivity vehicles and we're starting to notice that enterprise Go from $three million to $5 million. So we're hoping that would double once more, offers us a lot more diversification, and they are working with different information heart classification of customers.

    So they regain that greater assorted. So again, they are still taking pictures. Their goal has complete the time been to regain vigour to that consistent 10% multiply over a two to three-12 months period.

    Sean Hannan -- Needham and enterprise -- Analyst

    good enough. that's beneficial. and then closing query privilege here. just to notice if i will breathe able to regain some standpoint round a customer of yours without delay or ultimately.

    Huawei, I remember you might breathe now not necessarily even a 5% consumer, but are you able to focus on how upshot they play into your enterprise traditionally? And is there the comfort that they should still account of thinking about that relationship or income technology and maybe by some means tied to them on a go-forward groundwork? Thanks.

    Dan Bernstein -- President and Chief executive Officer

    neatly, I suppose, again, being a chinese language business, I reflect they are inclined to Go along with chinese providers in China. i know, for instance, they offered their dash provide neighborhood to Emerson about six years ago, and now former Huawei individuals own their own dash give company. So they know it's a troublesome nut to crack. They upshot some ICM enterprise, however no longer vast in any respect.

    And for us, it's going to breathe a strong handicap as a result of they reflect people enjoy Nortel, Cisco should still prefer up the company that they're losing. So i upshot know there are inescapable nations, Czech Republic, even Canada and the U.S. how they view Huawei going ahead. And that they cannot buy materiel from Huawei for 5G, they will doubtless Go with -- I failed to carryweight Nortel, I seekinformationfrom for forgiveness, Nokia, that Nokia and Cisco will likely elect up that slack and might breathe Alcatel, and these multinational non-chinese language purchasers they upshot gargantuan quantity of commerce with them.

    So we're hoping that their commerce should still multiply as more and more 5G is delivered.

    Sean Hannan -- Needham and company -- Analyst

    Very first rate. Thanks so tons, folks.


    [Operator instructions] And they will now elect a question from Hendi Susanto from G. analysis. gladden Go forward.

    Hendi Susanto -- G. analysis -- Analyst

    first rate morning. Dan, you commute to China a noteworthy deal. How upshot you signify your China market now? How different is it in comparison to a typical 12 months?

    Dan Bernstein -- President and Chief executive Officer

    We at complete times -- for us -- complete over the realm, I imply, Europe and China there may breathe so a lot uncertainty and how they dependence in Donald Trump and the job he's doing. there's giant amount of anxiousness. For us again, for the China market, or not it's always been very complex to wreck into that market as a result of the pricing parameters that you've got promoting to, again, a chinese language consumer. although, a top-notch component can breathe 35% of their sales Go to China, but it surely goes throughout the CEM enjoy the Flextronics or Hon Hai, Foxconn, and those are non-chinese groups.

    youngsters, they upshot -- they are starting to notice more americans watch at China in a distinct easy. They recognize the ODMs in Taiwan, they own majority of their production in China. They at the flash are piteous a few of that creation lower back into Taiwan. They notice other multinationals relocating products round to regain across the tariffs.

    So when you've got production in Malaysia, utilize that for complete items coming to the States after which you utilize your China production to Go into Europe and the a long pass East market. but once again, no one likes uncertainty and that without query with the tariffs there's giant amount of uncertainties and that's not first rate for anyone.

    Hendi Susanto -- G. research -- Analyst

    got it. after which Dan, given solid income growth and your backlog boom in 2018 and existing ERP implementation, how a top-notch deal development in uncouth margin and working margin they should expect in 2019?

    Dan Bernstein -- President and Chief executive Officer

    i will depart that to my accounting neighborhood here.

    Craig Brosious -- vice president of Finance

    yes. I account assuming the within your budget sales multiply that we're expecting, moderate income increase, I believe they own some leverage means to movement the uncouth margin up to maybe a point, aspect and a half. once more, lots of their construction costs are primarily based in the -- in China and counting on which approach the trade agreements go, it may own an upshot on the change fees that they should deal with on the can suffuse of that -- on the labor costs, exceptionally. So barring any massive moves in these change charges, we've opportunities to extend margins a bit bit.

    Hendi Susanto -- G. research -- Analyst

    after which a further question on charge. So I reflect Bel Fuse is coping with enhance in labor charge, and that i suppose that has been there for a long time after which you were mitigating or taking movements or improved your labor charge. after they slip through enjoy 2019, when can they examine on an apple-to-apple 12 months-over-12 months assessment in regards to the labor can charge? And enjoy how -- and then breathe certain you breathe in a position to quantify how an poor lot labor suffuse become?

    Craig Brosious -- vice chairman of Finance

    I believe they -- to regain to an apples-to-apples comparison, they are able to likely should regain within the third quarter of this year because they had suffuse raises going into impact within the first and second quarters of 2018. So I feel as soon as they regain to the third quarter, they regain some low cost comparatives.

    Lynn Hutkin -- Director of fiscal Reporting

    The most efficacious aspect to add there's, in 2019, we're also experiencing elevated labor suffuse in Mexico so that you can handle the 2019 length, however changed into not there privilege through the 2018 period. So they own that as smartly.

    Hendi Susanto -- G. analysis -- Analyst

    adequate. and then the majority of the tariff cost has been passed to clients. can you quantify how a noteworthy deal has been handed and what's next?

    Dan Bernstein -- President and Chief executive Officer

    I account it's been about $7.eight million, in that latitude.

    Lynn Hutkin -- Director of fiscal Reporting

    In 2018, it become about $2.four million, in total for 2018, in order that become a partial -- that was a partial 12 months.

    Craig Brosious -- vice chairman of Finance

    So enjoy Dan had mentioned previously, most of their sales as a minimum coming out of China don't become without delay into the U.S. So we're not enormously impacted through the tariffs. So they own been capable of -- basically $2.5 million or in order that they needed to add.

    Hendi Susanto -- G. analysis -- Analyst

    good enough. acquired it. thanks.


    [Operator instructions] It appears there aren't any additional questions. Mr. Bernstein, i would enjoy to demonstrate the muster back to you for any additional or closing remarks.

    Dan Bernstein -- President and Chief govt Officer

    thank you for joining us nowadays, and they look to talking to you sooner or later. thanks to your time.


    [Operator signoff]

    length: 29 minutes

    call members:

    Dan Bernstein -- President and Chief government Officer

    Lynn Hutkin -- Director of monetary Reporting

    Craig Brosious -- vp of Finance

    Sean Hannan -- Needham and enterprise -- Analyst

    Hendi Susanto -- G. research -- Analyst

    greater BELFB analysis

    this article is a transcript of this convention muster produced for The Motley fool. while they try for their silly premier, there could breathe mistakes, omissions, or inaccuracies during this transcript. as with complete their articles, The Motley fool does not assume any responsibility for your utilize of this content material, and they strongly animate you to upshot your personal analysis, together with listening to the muster yourself and analyzing the business's SEC filings. gladden notice their phrases and conditions for additional details, together with their mandatory Capitalized Disclaimers of liability.

    10 shares they enjoy enhanced than Bel FuseWhen investing geniuses David and Tom Gardner own a stock tip, it can pay to hear. in spite of everything, the e-newsletter they've dash for over a decade, Motley fool stock marketing consultant, has quadrupled the market.*

    David and Tom simply printed what they harmonize with are the 10 finest stocks for investors to buy privilege now... and Bel Fuse wasn't one in complete them! it's confiscate -- they reflect these 10 stocks are even more advantageous buys.

    See the ten stocks

    *stock marketing consultant returns as of January 31, 2019

    Motley fool Transcribing has no situation in any of the shares mentioned. The Motley idiot has no position in any of the shares mentioned. The Motley fool has a disclosure policy.

    Bel Fuse Inc. (BELFB) CEO Daniel Bernstein on this autumn 2018 consequences - income cognomen Transcript | actual Questions and Pass4sure dumps

    No result discovered, are trying current keyword!Bel Fuse Inc. (NASDAQ:BELFB) this drop 2018 results profits convention muster February 21 ... exact for their dash substances in diversity of data middle purposes. earnings of their DC to DC and circuit ...

    While it is hard errand to pick solid certification questions/answers assets regarding review, reputation and validity since individuals regain sham because of picking incorrectly benefit. ensure to serve its customers best to its assets as for exam dumps update and validity. The greater portion of other's sham report objection customers advance to us for the brain dumps and pass their exams cheerfully and effortlessly. They never compact on their review, reputation and property because killexams review, killexams reputation and killexams customer certitude is imperative to us. Extraordinarily they deal with review, reputation, sham report grievance, trust, validity, report and scam. On the off haphazard that you notice any wrong report posted by their rivals with the cognomen killexams sham report grievance web, sham report, scam, protestation or something enjoy this, simply remember there are constantly terrible individuals harming reputation of top-notch administrations because of their advantages. There are a noteworthy many fulfilled clients that pass their exams utilizing brain dumps, killexams PDF questions, killexams actual questions questions, killexams exam simulator. Visit, their example questions and test brain dumps, their exam simulator and you will realize that is the best brain dumps site.

    Back to Brain dumps Menu

    000-137 free pdf | M9560-760 braindumps | TK0-201 brain dumps | OG0-9AB questions and answers | HP2-E15 actual questions | 1Z0-567 rehearse test | 000-318 pdf download | 00M-230 cheat sheets | CISM mock exam | A2040-956 free pdf download | 650-575 rehearse Test | 1Z0-547 bootcamp | M2010-719 examcollection | 650-316 rehearse test | 270-411 free pdf | 77-883 rehearse test | 1Z0-325 sample test | 1Z0-599 braindumps | 000-913 exam prep | 000-005 rehearse questions |

    Ensure your success with this 920-106 question bank
    Is it accurate to negate that you are searching for Nortel 920-106 Dumps of actual questions for the NNCSS SYMPOSIUM muster heart Exam prep? They give as of late refreshed and incredible 920-106 Dumps. Detail is at They own gathered a database of 920-106 Dumps from actual exams on the off haphazard that you exigency to can enable you to assemble and pass 920-106 exam on the first attempt. Simply set up together their actual questions and unwind. You will pass the exam. high value 920-106 exam simulator will breathe facilitating for their customers for the test steering. complete vital functions, rehearse questions and definitions are highlighted in 920-106 brain dumps pdf. Gathering the records in one region will breathe a actual time saver and makes you confident for the NNCSS SYMPOSIUM muster heart exam within a brief time span. The 920-106 exam provides key points. The with pass4sure dumps permits to memorize the essential questions or concepts of the 920-106 exam At, they tender absolutely verified Nortel 920-106 rehearse questions that are the satisfactory for Passing 920-106 exam, and to induce certified with the assistance of 920-106 braindumps. It is a top-notch option to accelerate your career as a specialist within the Nortel Technology. they are pleased with their property of supporting humans pass the 920-106 exam of their first attempt. Their success fees at intervals the past 2 years were certain enough gorgeous, because of their ecstatic shoppers currently ready to boost their career at the quick lane. is the primary preference among IT specialists, above complete those are trying to climb up the hierarchy of qualifications faster in their respective organization. Nortel is the enterprise leader in info generation, and obtaining certified will breathe assured to succeed with IT careers. they own an approach to assist you with their immoderate best Nortel 920-106 brain dumps. helps millions of candidates pass the exams and regain their certifications. They own thousands of successful reviews. Their dumps are reliable, affordable, updated and of really best property to overcome the difficulties of any IT certifications. exam dumps are latest updated in highly outclass manner on regular basis and material is released periodically. Latest dumps are available in testing centers with whom they are maintaining their relationship to regain latest material.

    The exam questions for 920-106 NNCSS SYMPOSIUM muster heart exam is mainly based on two accessible formats, PDF and rehearse questions. PDF file carries complete the exam questions, answers which makes your preparation easier. While the rehearse questions are the complimentary feature in the exam product. Which helps to self-assess your progress. The evaluation tool also questions your fragile areas, where you exigency to redeem more efforts so that you can help complete your concerns. recommend you to must try its free demo, you will notice the intuitive UI and also you will find it very simple to customize the preparation mode. But obtain certain that, the actual 920-106 product has more features than the visitation version. If, you are contented with its demo then you can purchase the actual 920-106 exam product. Avail 3 months Free updates upon purchase of 920-106 NNCSS SYMPOSIUM muster heart Exam questions. offers you three months free update upon acquisition of 920-106 NNCSS SYMPOSIUM muster heart exam questions. Their expert team is always available at back conclude who updates the content as and when required. Huge Discount Coupons and Promo Codes are as under;
    WC2017 : 60% Discount Coupon for complete exams on website
    PROF17 : 10% Discount Coupon for Orders greater than $69
    DEAL17 : 15% Discount Coupon for Orders greater than $99
    DECSPECIAL : 10% Special Discount Coupon for complete Orders

    920-106 Practice Test | 920-106 examcollection | 920-106 VCE | 920-106 study guide | 920-106 practice exam | 920-106 cram

    Killexams LOT-803 rehearse test | Killexams C9010-262 questions answers | Killexams 9A0-381 sample test | Killexams 000-918 actual questions | Killexams P2170-035 exam prep | Killexams MSC-321 study guide | Killexams C2090-603 exam prep | Killexams 1Z0-932 cram | Killexams 310-875 rehearse questions | Killexams CWNA-107 questions and answers | Killexams 1Z0-439 rehearse exam | Killexams 000-651 pdf download | Killexams NCPT actual questions | Killexams 000-451 rehearse test | Killexams MSC-331 questions and answers | Killexams ST0-086 examcollection | Killexams 1Z0-100 actual questions | Killexams HP2-H65 rehearse test | Killexams 70-565-VB bootcamp | Killexams 000-N19 test questions |

    Exam Simulator : Pass4sure 920-106 VCE Exam Simulator

    View Complete list of Brain dumps

    Killexams HP2-E46 free pdf | Killexams SK0-004 actual questions | Killexams HP0-092 rehearse test | Killexams 00M-194 pdf download | Killexams 000-208 rehearse questions | Killexams APA-CPP study guide | Killexams 050-644 test prep | Killexams HP2-E15 dumps questions | Killexams MB2-527 rehearse Test | Killexams HP2-B121 examcollection | Killexams P2170-036 questions and answers | Killexams 3I0-012 test prep | Killexams C2090-625 free pdf | Killexams 700-270 rehearse questions | Killexams MOS-A2K cheat sheets | Killexams 310-065 exam questions | Killexams 000-976 cram | Killexams PCCE test prep | Killexams LOT-915 rehearse exam | Killexams 050-CSEDLPS test questions |


    Pass 4 certain 920-106 dumps | 920-106 actual questions |

    Strongbridge Biopharma plc (SBBP) Q4 2018 Earnings Conference muster Transcript | actual questions and Pass4sure dumps

    Logo of jester cap with thought bubble.

    Image source: The Motley Fool.

    Strongbridge Biopharma plc  (NASDAQ:SBBP)Q4 2018 Earnings Conference CallFeb. 26, 2019, 8:30 a.m. ET

  • Prepared Remarks
  • Questions and Answers
  • Call Participants
  • Prepared Remarks:


    Good morning, ladies and gentlemen, and welcome to the Strongbridge Biopharma Corporate Update and Fourth Quarter 2018 Earnings Conference Call. At this time, complete participants are in a listen-only mode. Later they will conduct a question-and-answer session and instructions will ensue at that time. (Operator Instructions) As a reminder, this muster will breathe recorded.

    I would now enjoy to introduce your host for today's conference, Ms. Lindsay Rocco of Elixir Health Public Relations. You now may begin.

    Lindsay Rocco -- Investor Relations

    Thank you and top-notch morning, everyone. They are pleased that you could link us today for Strongbridge Biopharma's fourth quarter and full year 2018 earnings conference call. Joining me from Strongbridge this morning are Matthew Pauls, President and Chief Executive Officer; Dr. Fred Cohen, Chief Medical Officer; and Brian Davis, Chief fiscal Officer.

    Before they begin, I would enjoy to remind you that during this call, the Company will breathe making forward-looking statements that are theme to risks and uncertainties that may antecedent actual results to differ from the results discussed in the forward-looking statements. Reference to these risks and uncertainties are made in today's press release and disclosed in detail in the Company's sporadic and current event filings with the U.S. Securities and Exchange Commission.

    In addition, this presentation includes non-GAAP fiscal measures. This presentation is not intended to breathe a substitute for fiscal results presented in conformity with generally accepted accounting principles in the U.S. Investors and potential investors are encouraged to review the reconciliation of the pro forma fiscal measures included in the Company's earnings release. The most directly comparable GAAP information and a reconciliation between the non-GAAP and GAAP figures are included in the Company's fourth quarter 2018 earnings release, which has been furnished on contour 8-K.

    I will now rotate the muster over to Matthew Pauls.

    Matthew Pauls -- President and Chief Executive Officer

    Thank you, Lindsay. top-notch morning everyone and thanks for joining us. For today's call, I'll initiate by providing a brief summary of their fourth quarter and full year 2018 highlights and results. And then we'll rotate the muster over to Dr. Fred Cohen, their Chief Medical Officer, to argue the ongoing side III clinical development program for RECORLEV. Brian Davis, their Chief fiscal Officer, will then provide a fiscal overview. They will then open up the muster for questions.

    With that, let me start by proverb that Strongbridge had a strong fourth quarter from a clinical, commercial and fiscal perspective, which is a reflection of their momentum and overall success throughout the past year. As you will hear from the team today, their accomplishments in 2018 demonstrate the value of their rare disease strategy and own positioned us for future growth as they continue to identify, develop and commercialize notable treatments for rare diseases. Leveraging the momentum from ultimate year, they entered 2019 with a focus on progressing the development of RECORLEV for the treatment of endogenous Cushing's syndrome.

    And getting into their most notable fourth quarter accomplishments, let's start with the Novo Nordisk transactions. In December, they significantly strengthened their balance sheet with the sale of the U.S. and Canadian rights of MACRILEN to Novo Nordisk. As previously mentioned, a portion of the upfront cash payment of $145 million from Novo Nordisk to Strongbridge was used to repay complete outstanding debt. Other key terms from the transaction comprise that Strongbridge will receive royalties on MACRILEN sales through 2027. And in addition, Novo Nordisk purchased 5.2 million ordinary shares of Strongbridge at a purchase cost of $7 per share, resulting in uncouth proceeds of $36.7 million.

    Another notable key strategic term of the transaction is that Novo Nordisk will fund Strongbridge's 23-person rare endocrine commercial realm organization over the next three years to promote MACRILEN in the United States. This aligns with the Company's objective to maximize the potential of MACRILEN, while preparing for the potential regulatory approval of RECORLEV in endogenous Cushing's syndrome, a rare condition that's often treated by the selfsame endocrinologist that diagnose and deal adult growth hormone deficiency.

    Onto their rare neuromuscular franchise. KEVEYIS, their first commercial product, enabled us to build out a rare neuromuscular franchise, which continues to breathe a strategic pillar for the Company. They are committed to serving the needs of the primary sporadic paralysis, or PPP community, which is comprised of an estimated 4,000 to 5,000 currently diagnosed patients in the United States. As they prepare for the regulatory filing of potential launch of RECORLEV, there are many parallels and learnings that they own garnered from the KEVEYIS opening that they own and will continue to leverage across their business.

    Additionally, they believe that the undergo and knowledge gained from launching KEVEYIS best positioned Strongbridge to acquire the rights to MACRILEN early ultimate year, before selling the rights to Novo Nordisk at the conclude of the year. As portion of their life cycle management planning for KEVEYIS, they are executing on a number of initiatives with the primary objective of maximizing the value of KEVEYIS over time. They believe that by the conclude of 2019 or into early 2020 that they will breathe in a position to provide an update on their life cycle management progress.

    Our investment approach with KEVEYIS focuses on three key areas. Specifically, they are focusing their KEVEYIS commercial investment on, one, utilizing sophisticated data to identify physicians that deal PPP; two, fully leveraging their CareConnection patient services model; and three, engaging the PPP community through both patient advocacy, as well as targeted convivial media. They watch forward to executing against their 2019 plans and believe that KEVEYIS will generate a positive contribution margin by the conclude of the first quarter of 2020.

    So with that I'll rotate the muster over to Dr. Fred Cohen, their Chief Medical Officer, to argue their clinical development progress for RECORLEV, which they believe continues to own the potential to breathe a first-line, first-choice therapy for patients with endogenous Cushing's syndrome.

    I will now rotate the muster over to Fred.

    Fredric Cohen -- Chief Medical Officer

    Thank you, Matt. top-notch morning, everyone. As previously announced in the third quarter, the pivotal side III SONICS study of RECORLEV for the treatment of endogenous Cushing's syndrome met its primary endpoint, with urinary free cortisol or UFC confirmed (ph) as simple among 30% of the intent to deal population at the conclude of the six-month maintenance phase.

    Detailed initial results from the SONICS study were presented in October at the European NeuroEndocrine Association Annual Meeting, with additional data presented at the European Network for the study of Adrenal Tumors Annual Meeting in November. These analyses illustrated the favorable effects of RECORLEV on hypercortisolism and its comorbidities, particularly sustained improvements in markers of cardiovascular risk, such as LDL-cholesterol, hemoglobin A1C and cadaver weight.

    Further SONICS results from the conclude of maintenance analyses are planned for presentation at the International Pituitary Congress and the Endocrine Society's Annual Meetings in late March, and at the American Association of Clinical Endocrinology Meeting in April. These results will highlight additional benefits of RECORLEV on the signs and symptoms of hypercortisolism.

    Additionally, submission of a manuscript of the primary efficacy and safety data from SONICS to a peer-reviewed journal is anticipated in the first half of 2019. One-year data from the completed SONICS study are expected to breathe available in the first half of 2019. These data will comprise findings from the six-month extended evaluation phase, which is primarily intended to characterize the long-term safety, tolerability and benefit-risk profile of RECORLEV.

    From a regulatory standpoint, a ilk C meeting with the FDA is planned within this quarter to search guidance on the path forward to obtain marketing approval for RECORLEV in the United States, and that process is on track. They anticipate providing an update in the second quarter.

    Finally, the receipt of top line results from the side III LOGICS study remains on track for the fourth quarter of 2019. As a reminder, LOGICS is a double blind visitation with no planned interim analyses prior to the receipt of these anticipated results.

    And with that, I will now rotate the muster over to Brian Davis for a fiscal overview.

    A. Brian Davis -- Chief fiscal Officer

    Thank you, Fred. Their press release hold details of their fiscal results for the fourth quarter and full year 2018. Rather than read complete of those details, my comments will heart on a few highlights.

    As famous in the press release, their guidance for KEVEYIS revenues in 2019 is in the $18 million to $20 million range. They own significantly improved their fiscal and strategic flexibility as a result of the cash proceeds and anticipated future payments from their transactions with Novo Nordisk, as well as the repayment in full of their outstanding debt. They ended 2018 with $122.5 million of cash, cash equivalents and no outstanding debt. As for cash runway, they believe the combination of their existing cash resources, anticipated KEVEYIS revenues and payments from Novo Nordisk, as well as the continued prudent management of their operating expenses will provide sufficient capital to advocate their operations, at least through the first quarter of 2021.

    And Catherine, with that, they are now ready to open up the muster for questions.

    Questions and Answers:


    (Operator Instructions) And their first question comes from Esther Hong with Janney. Your line is open.

    Esther Hong -- Janney -- Analyst

    Hi, top-notch morning. Thanks for taking my questions. So with respect to the ilk C FDA meeting over RECORLEV, can you provide additional details on your expectations, and then, any potential logistics regarding accelerator approval? And then the second question is, any updates on commerce development plans in 2019? Thanks.

    Matthew Pauls -- President and Chief Executive Officer

    So Esther, this is Matt. Thank you for the questions. Let me elect them in invert order. With regard to commerce development, they obviously don't comment on any commerce development-related projects that they may breathe working on. I upshot reflect that their history here at Strongbridge -- as they continue to build the Company is that they are vigorous in looking at opportunities and that continues. And that's complete I'll negate on that front. I will own Dr. Cohen comment on the ilk C regulatory process and timing.

    Fredric Cohen -- Chief Medical Officer

    Sure. So as I've just -- they upshot blueprint to own the discussion with the FDA in the first quarter of this year, and then following digestion of that and then any clarifying dialog they exigency to own with the FDA, they blueprint to update investors by the second quarter with the path forward, as they said. In terms of their ground case, just to reiterate, they are anticipating that the FDA will lead us toward the exigency for both the full SONICS as well as the full LOGICS study for being in hand and included within NDA. Again, that's the ground case. The upside case for us that they believe is supported with the unmet medical need, the pass that SONICS was designed in terms of using a surrogate endpoint that's been established, and the precedent within this division of allowing approval on the basis of the lone open label study, they believe that there is an upside case where there could breathe an accelerated pathway toward the filing, where they ground it primarily just on the SONICS, to your point around accelerator approval. Again, they upshot reflect that the dialog that we're anticipating with the FDA in this quarter will obtain that pathway limpid for us and then we'll update you guys accordingly.

    And with regard to timing, that's just so -- in the expedited or accelerated upside case, clearly they would breathe working hard to regain it -- regain the NDA filed as quickly as possible, probably realistically why they would carefor to own it filed by the conclude of the year, at the conclude of 2019, it probably would breathe more enjoy an early 2020-ish. More details to advance on that, obviously, as they own more clarity. In the ground case, it would breathe about a year later than that. I hope that helps.

    Esther Hong -- Janney -- Analyst

    It does. Great, thank you.

    Fredric Cohen -- Chief Medical Officer

    You are welcome.


    Thank you. And their next question comes from Annabel Samimy with Stifel. Your line is open.

    Nick Rubino -- Stifel -- Analyst

    Good morning, everyone. This is Nick Rubino on for Annabel Samimy. Thanks for taking their question. First, how the efforts to educate physicians on titration helped patient retention. Are you still seeing attrition due to the side effects and how upshot you notice those dynamics playing out 2019 and beyond? And then second with the one-year SONICS, you had mentioned the safety pieces, but are they getting efficacy measures as well? And then, if I can just sneak in a quick hastily one, with the MACRILEN revenue numbers you reported this quarter, are those purely royalty revenues or did those comprise full sales from October and November? Thanks.

    Matthew Pauls -- President and Chief Executive Officer

    Thanks for those questions, Nick. Let me give you a puny insight on the first question regarding KEVEYIS. They learned a lot on the KEVEYIS fronts in 2018 regarding both KEVEYIS as well as primary sporadic paralysis. And one of the key learnings which you well said was around the need, often to Go a puny bit lower and a puny bit slower in the titration period. And, I'll seekinformationfrom Dr. Cohen just to comment briefly on that. I think, they own some learnings from side III visitation and then from the clinical -- not just clinical instant -- in the clinical trial, but also in the commercial utilize too. So, Fred, upshot you want to comment on that?

    Fredric Cohen -- Chief Medical Officer

    Yeah. Yeah, sure. Great. So one of the things that they learned was that there are a significant minority of patients who experienced adverse reactions from the drug early on in the therapy. And one of them -- one of those reactions that's common is on -- a confusion on mental fog, if you will, that occurs. It's a momentary response to the drug until the brain can sort of equilibrate and become used to the drug. But when it occurs, it needs to breathe addressed, it needs to breathe managed, and the best pass that they know how to manage it is by lowering the dose of the drug.

    Well, it took us a while, I think, number one, to recognize that this was a reaction that was accountable for some patients discontinuing from the drug. And once they did recognize that, they redeem in situation a chain of educational efforts aimed at physicians initially and then later direct-to-patient education and supervision through the utilize of, for example, patient ambassadors that own given their time generously to serve educate other patients. And so we're making noteworthy progress. I think, it's objective to negate we've seen already changes in the pass the titrations are going. And we've gotten feedback from patients who are now able to overcome the initial side-effects and own stayed on the drug, because they are seeing benefits from it in many cases. So, I hope that addresses that portion of that question.

    Nick Rubino -- Stifel -- Analyst

    Yes, that's great. Then, with regards to the --

    Matthew Pauls -- President and Chief Executive Officer

    Yes, the MACRILEN revenues during the fourth quarter were product sales by Strongbridge. There were no royalties in their revenues for the quarter.

    Fredric Cohen -- Chief Medical Officer

    Yes, there was also a question you had about the 1-year RECORLEV data. So on the top line data that they will breathe sharing with you will comprise primarily safety data. But also they did measure some efficacy data as well, including urine free cortisol, as well as those comorbidity markers. And I'm pretty certain we'll breathe sharing that with you at the time they release the top line results.

    Nick Rubino -- Stifel -- Analyst

    Alright. Great. Thank you guys.

    Matthew Pauls -- President and Chief Executive Officer

    Yes, thanks for the questions.


    Thank you. And their next question comes from Hartaj Singh with Oppenheimer & Company. Your line is open.

    Hartaj Singh -- Oppenheimer & Company -- Analyst

    Great, thanks. Thanks for the question and a top-notch year. Just a brace of questions, Matt I've got. On your interactions with the FDA prior to this meeting, I assume you might own already submitted a sort of a briefing package and benevolent of there own been some interactions back and forth. Can you just give some color on, sort of, the gist of those interactions and what are some of the questions that maybe you're asking or FDA is wanting to breathe addressed prior to the actual meeting? And then a second question, just on KEVEYIS, to ensue up with the previous question. Matt, can you just give some color on, sort of, current patients, continuing patients, what sort of -- how many patients are staying on drug, on average, just any color around what that dynamic is, because it seems that the drug is growing quarter-on-quarter. And then just your thoughts about that going forward. And then just a quick housekeeping question after that. Thank you.

    Matthew Pauls -- President and Chief Executive Officer

    Great, thank you Hartaj. So on the regulatory question related to RECORLEV. As a benchmark course for us, they don't comment on the interactions prior to having their final interpretation of the dialog. So more to advance in the second quarter. And I think, Fred articulated well earlier what their ground case assumptions are meeting both trials and the upside case around an accelerated potential approval, given the significant unmet exigency in Cushing syndrome, UFC being a stated accepted surrogate endpoint by the FDA, resoundingly positive, and they reflect compelling SONICS data. And then, in this division, in the review of Cushing's syndrome, lone visitation approvals. So that's where we're at and we'll provide an update in the second quarter.

    And then with regard to KEVEYIS -- and your question on KEVEYIS. So what they know is that there -- they are confident there are 4,000 to 5,000 patients currently diagnosed with PPP. They are seeing current patients regularly advance onto KEVEYIS. And they are doing a much better job, as Fred mentioned, with regard to patient-to-patient interaction, patient-to-physician interaction, recommendations around maybe lower and slower titration or down titration. So they are seeing patients more often than not -- now wait on the drug through that benevolent of an interim period.

    And so, the gargantuan focus for us here is being smart and choiceful about their investment flat with regard to KEVEYIS, because it's notable for many reasons to try to drive KEVEYIS to profitability on a stand-alone basis as quickly as possible. And we're confident that we're on that path by the conclude of the first quarter of 2020. And parallel to that, given the fact that there are no other drugs really that are in development for the treatment of this ultra-rare genetic neuromuscular condition, PPP, they are working very feverishly and hard, as we've said previously, around life cycle management opportunities. They would carefor to own the opening to own more runway with KEVEYIS. So more to advance by the -- probably by the conclude of the year, again, maybe into 2020 on their life cycle management plans. But this is a market that prior to us relaunching the drug really had no investment ever, was disorganized, unstructured. And we're confident that we're on the path to structuring it, organizing it and getting KEVEYIS to profitability, so that we're being smart and choiceful and sane with regard to their investment.

    Hartaj Singh -- Oppenheimer & Company -- Analyst

    Great. And Matt, that's noteworthy color. Just a follow-up on that. So roughly speaking, are you sort of seeing patients that are coming that are current to KEVEYIS being equal to patients dropping off, or is there less of a drop-off, just what's the dynamic there between the current and the continuing patients and the patients that are leaving, whether it's titration or for other issues?

    Matthew Pauls -- President and Chief Executive Officer

    So, they -- the trend is that more patients are staying on the drug than off. And that's based on the interventions, really in -- I guess in the back half of the third quarter and the fourth quarter by us, and of course to-date. So what we're -- the patient identification and identifying patients who are very motivated and physicians that are motivated and then providing the very strong flat of advocate and service for them through that process, given the potency of KEVEYIS. I carryweight the drug really works. It really works. They are having success getting patients through that short -- I don't know -- for a four-to-six-week period-ish, that range. But it's upwards of eight weeks.

    Hartaj Singh -- Oppenheimer & Company -- Analyst

    Got it. And then just one housekeeping question on -- just how to reflect about operating expenditures, sort of, going forward for the year, just any thoughts there? And again, thank you so very much.

    Matthew Pauls -- President and Chief Executive Officer

    Yes, Hartaj. This is Brian, Hartaj. Thanks for that. So, on the cash basis, as I mentioned, we're looking at a runway that takes us through the first quarter of 2021. I reflect they own the profit of the Novo Nordisk subsidy coming online here in 2019 to offset the commercial trouble around MACRILEN. And so we'll own a puny transition working through Q1 to regain down on a cash parch basis. But they feel pretty cozy in that low-to-mid teens area as they slip forward. In fact, if you elect that $122 million cash balance and just by simple averaging over the subsequent nine quarters through the first quarter of 2021 that comes up to about $13.5 million. So a puny more in this year, reflecting the transition down, reflecting we've got some increased RECORLEV program expenses (inaudible) high water mark, if you will, for the RECORLEV program, because they own SONICS and LOGICS and OPTICS running simultaneously, but obviously SONICS expense is winding down now that the one-year data will breathe coming through. So again, enough cash to regain us at least through the first quarter. And obviously, we'll own more definition on that as they Go along as to how much more at least it can be.

    Hartaj Singh -- Oppenheimer & Company -- Analyst

    Great. And I really cherish it. Thank you very much.


    Thank you. And their next question comes from Liisa Bayko with JMP Securities. Your line is open.

    Liisa Bayko -- JMP Securities -- Analyst

    Hi, congratulations on the quarter. Just a brace of questions for me, mainly about KEVEYIS. So first of all, I want to negate congratulations, I carryweight you've made this into a product that reached $20 million this year, which is certainly a lot higher than where you thought the product brace of years ago. They technically were only talking about $1 million. So it's obvious that you've done a tremendous job in creating this market. But again (ph) your guidance a puny bit, for this year, looks enjoy $4.4 million is the benevolent of what you're coming off 4Q (ph). Your guidance of $18 million to $20 million implies a puny bit of slowing growth. So is that -- are patients adds still happening at the selfsame rate or is that lower, are you having -- struggling to find more patients or is it based on -- basically from your comments, I'm thinking maybe less revenue per patient because of dose titration. What's the benevolent of dynamic with add indications or revenue per patient? How does that -- what's sort of underlying the guidance?

    A. Brian Davis -- Chief fiscal Officer

    Yes, this is Brian. So again, we're continuing the top-notch news, is find patients. And they feel really top-notch about the realm force they own in situation and they're performing very strongly, as Matt indicated in his comments and in the prior answer. We've had a lot of learning in this market and working through how best not only to attract patients, but also to retain patients. So they were conscious of the revenue ambit that they redeem out there, $18 million to $20 million and where we've advance off of this year, we're going to breathe conservative in their approach, But the patient retention piece takes time and they reflect we're working through it.

    On the expense side, they own focused their investment and made decisions to abate the territories to serve obtain certain they regain to a positive contribution margin or a profitability standpoint for the product. They went from 21 down to 17 territories. They focused their marketing expenses to those -- really targeted toward the patient, in order to serve complete of the revenue expenses to line up. So, we'll preserve working through it, but they feel top-notch about their talent to not only hit this range, but also to regain this product to breathe one that's a profitable one. And as you pointed out at the beginning, it was a very challenging market to enter into. You're quite correct. Before they had acquired the drugs -- the drug, I should say, its sales had been less than $1 million in a year. So, yes.

    Matthew Pauls -- President and Chief Executive Officer

    Yes, so Liisa, the other piece on that to note is, as I mentioned, in parallel, they are looking at life cycle management opportunities and we'll update the market probably by the conclude of the year or in early 2020. And if there are potential opportunities to extend the life and runway of KEVEYIS, they will obviously, probably revisit their investment strategy with regard to the brand. But privilege now, it is to regain it to profitability as quickly as possible and to grow the top line, which they will upshot both. And exiting the year, the low conclude of the range, we're tracking already to the low conclude of the range. So hopefully, there will breathe some -- even more enhanced or increased momentum as they Go the year.

    Liisa Bayko -- JMP Securities -- Analyst

    Okay, objective enough. And then, I guess, as you watch longer-term, are you still thinking this product is benevolent of easily a brace hundred million or upshot you own some other benevolent of target in intelligence longer-term now that you've had more undergo selling the drug? Just thinking about how, benevolent of, directionally where they should breathe headed in terms of modeling. Thanks.

    A. Brian Davis -- Chief fiscal Officer

    I reflect -- this is Brian. I think, there's a brace of things there, Liisa, that really play into that. So one is the patient penetration. So they reflect we've got an opening and we're really just at the beginning stages of it in terms of patient penetration. Now Matt and Fred were taking a puny bit earlier about life cycle management opportunities, having a longer commercial runway will certainly allow us the opening to achieve peak sales levels over a longer era of time that they own (inaudible). We're just operating with the current regulatory exclusivity. I think, the other piece that obviously plays into in this environment is around the cost of the drug. And I would note, they continue to breathe very cautious in their thinking around that. So we'll talk about pricing strategy, specifically, but we're very awake of the environment that we're in and we're going to act appropriately in that environment, and really try to upshot complete they can to obtain certain patients -- as many patients own access to the drug as possible over time. But they reflect there's a longer runway in terms of reaching out to patients and life cycle management opportunities would certainly serve to regain us up to higher peak sales levels.

    Liisa Bayko -- JMP Securities -- Analyst

    Okay. Thank you very much for your comments. cherish it.

    A. Brian Davis -- Chief fiscal Officer

    Thanks Liisa.


    Thank you. And I'm showing no further questions at this time. I'd enjoy to rotate the muster back to Mr. Matthew Pauls for any closing remarks.

    Matthew Pauls -- President and Chief Executive Officer

    Thank you. In summary, these fourth quarter and full year 2018 results underscore that their strategy, their assets, their people, their capital and their infrastructure well position us for continued success in 2019 and beyond. Thank you for joining today's muster and for your continued support.


    Ladies and gentlemen, thank you for participating in today's conference. This does conclude today's program. You may complete disconnect. Everyone own a noteworthy day.

    Duration: 33 minutes

    Call participants:

    Lindsay Rocco -- Investor Relations

    Matthew Pauls -- President and Chief Executive Officer

    Fredric Cohen -- Chief Medical Officer

    A. Brian Davis -- Chief fiscal Officer

    Esther Hong -- Janney -- Analyst

    Nick Rubino -- Stifel -- Analyst

    Hartaj Singh -- Oppenheimer & Company -- Analyst

    Liisa Bayko -- JMP Securities -- Analyst

    More SBBP analysis

    Transcript powered by AlphaStreet

    This article is a transcript of this conference muster produced for The Motley Fool. While they strive for their silly Best, there may breathe errors, omissions, or inaccuracies in this transcript. As with complete their articles, The Motley Fool does not assume any responsibility for your utilize of this content, and they strongly animate you to upshot your own research, including listening to the muster yourself and reading the company's SEC filings. gladden notice their Terms and Conditions for additional details, including their Obligatory Capitalized Disclaimers of Liability.

    Motley Fool Transcribers has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

    Nektar Therapeutics to Webcast Conference muster for Analysts and Investors at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium | actual questions and Pass4sure dumps

    SAN FRANCISCO, Feb. 25, 2019 /PRNewswire/ -- Nektar Therapeutics (NKTR) announced today that it will webcast an analyst and investor conference muster with lead investigator of the REVEAL study, Dr. Adi Diab, and company management on Friday, March 1, 2019 at 3:00 p.m. Pacific Time during the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium. The event will ensue Friday's oral presentation by Dr. Diab of introductory data from the ongoing dose-escalation stage of the expose side 1/2 clinical study evaluating the combination of TLR agonist, NKTR-262, with a CD122-preferential IL-2 pathway agonist, bempegaldesleukin* (NKTR-214), in patients with locally advanced or metastatic solid tumors.

    Details on the Analyst Call:

    Date and Time: Friday, March 1, 2019 at 3:00 p.m. Pacific Time

    Dial-in: 877-881-2183 (toll-free) or 970-315-0453 (international)

    Passcode: 6970019

    The conference muster will include lead investigator on the expose study, Dr. Adi Diab, aide Professor of Melanoma Medical Oncology at The University of Texas MD Anderson Cancer Center. The webcast and slides for the conference muster can breathe accessed through a link that is posted on the Investors section of the Nektar website at The event will also breathe available for replay for two weeks on the company's website,

    Details on the Oral Presentation at ASCO-SITC:

    Abstract Title: "Phase Ib: introductory clinical activity and immune activation for NKTR-262 [TLR 7/8 

    agonist] plus NKTR-214 [CD122-biased agonist] in patients (pts) with locally advanced or metastatic solid

    tumors (REVEAL side Ib/II Trial)"

    Abstract: #28

    Presenter: Dr. Adi Diab, MD Anderson Cancer Center

    Session: Oral Abstract Session B

    Date and Time: Friday, March 1, 2019, 1:00 p.m.-2:15 p.m. Pacific Time

    About NektarNektar Therapeutics is a research-based, development stage biopharmaceutical company whose mission is to ascertain and develop innovative medicines to address the unmet medical needs of patients. Their R&D pipeline of current investigational medicines includes treatments for cancer, auto-immune disease and inveterate pain. They leverage Nektar's proprietary and proven chemistry platform in the discovery and design of their current therapeutic candidates. Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may breathe institute online at

    * rINN (recommended International Nonproprietary Name)


    View original content:

    American Outdoor Brands Corporation® Third Quarter Fiscal 2019 fiscal Release and Conference muster Alert | actual questions and Pass4sure dumps

    SPRINGFIELD, Mass., Feb. 22, 2019 /PRNewswire/ -- American Outdoor Brands Corporation (nasdaq global select:AOBC) today announced that it plans to release its third quarter fiscal 2019 fiscal results on Thursday, March 7, 2019, after the near of the market. The full text of the press release will breathe available on the American Outdoor Brands web site at under the Investor Relations section.

    The company will host a conference muster and webcast on March 7, 2019, to argue its third quarter fiscal 2019 fiscal and operational results. Speakers on the conference muster will comprise James Debney, President and Chief Executive Officer, and Jeffrey D. Buchanan, Executive Vice President and Chief fiscal Officer. The conference muster may comprise forward-looking statements. The conference muster and webcast will initiate at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Those interested in listening to the conference muster via telephone may muster directly at (844) 309-6568 and reference conference identification number 9683518. No RSVP is necessary. The conference muster audio webcast can also breathe accessed live and for replay on the company's website at, under the Investor Relations section. The company will maintain an audio replay of this conference muster on its website for a era of time after the call. No other audio replay will breathe available.

    About American Outdoor Brands Corporation American Outdoor Brands Corporation (nasdaq global select:AOBC) is a provider of property products for shooting, hunting, and rugged outdoor enthusiasts in the global consumer and professional markets. The Company reports two segments: Firearms and Outdoor Products & Accessories. Firearms manufactures handgun long gun, and suppressor products sold under the Smith & Wesson®, M&P®, Thompson/Center Arms™, and Gemtech® brands, as well as provides forging, machining, and precision plastic injection molding services. AOB Outdoor Products & Accessories is the industry leading provider of shooting, reloading, gunsmithing, gun cleaning supplies, specialty tools and cutlery, and electro-optics products and technology for firearms. They bear innovative, top property products under the brands Caldwell®; Wheeler®; Tipton®; Frankford Arsenal®; Lockdown®; BOG®; Hooyman®; Smith & Wesson® Accessories; M&P® Accessories; Thompson/Center Arms™ Accessories; Schrade®; conventional Timer®; Uncle Henry®; Imperial®; BUBBA®; UST®;  Lasergrips®, Laserguard®, LiNQ®, Lightguard®, Defender Series™, Rail Master®, and LaserLyte.  For more information on American Outdoor Brands Corporation, muster (844) 363-5386 or log on to  

    Contacts:Liz Sharp, VP Investor RelationsAmerican Outdoor Brands Corporation(413)

    View original content to download multimedia:

    SOURCE American Outdoor Brands Corporation

    Copyright (C) 2019 PR Newswire. complete rights reserved

    Direct Download of over 5500 Certification Exams

    3COM [8 Certification Exam(s) ]
    AccessData [1 Certification Exam(s) ]
    ACFE [1 Certification Exam(s) ]
    ACI [3 Certification Exam(s) ]
    Acme-Packet [1 Certification Exam(s) ]
    ACSM [4 Certification Exam(s) ]
    ACT [1 Certification Exam(s) ]
    Admission-Tests [13 Certification Exam(s) ]
    ADOBE [93 Certification Exam(s) ]
    AFP [1 Certification Exam(s) ]
    AICPA [2 Certification Exam(s) ]
    AIIM [1 Certification Exam(s) ]
    Alcatel-Lucent [13 Certification Exam(s) ]
    Alfresco [1 Certification Exam(s) ]
    Altiris [3 Certification Exam(s) ]
    Amazon [2 Certification Exam(s) ]
    American-College [2 Certification Exam(s) ]
    Android [4 Certification Exam(s) ]
    APA [1 Certification Exam(s) ]
    APC [2 Certification Exam(s) ]
    APICS [2 Certification Exam(s) ]
    Apple [69 Certification Exam(s) ]
    AppSense [1 Certification Exam(s) ]
    APTUSC [1 Certification Exam(s) ]
    Arizona-Education [1 Certification Exam(s) ]
    ARM [1 Certification Exam(s) ]
    Aruba [6 Certification Exam(s) ]
    ASIS [2 Certification Exam(s) ]
    ASQ [3 Certification Exam(s) ]
    ASTQB [8 Certification Exam(s) ]
    Autodesk [2 Certification Exam(s) ]
    Avaya [96 Certification Exam(s) ]
    AXELOS [1 Certification Exam(s) ]
    Axis [1 Certification Exam(s) ]
    Banking [1 Certification Exam(s) ]
    BEA [5 Certification Exam(s) ]
    BICSI [2 Certification Exam(s) ]
    BlackBerry [17 Certification Exam(s) ]
    BlueCoat [2 Certification Exam(s) ]
    Brocade [4 Certification Exam(s) ]
    Business-Objects [11 Certification Exam(s) ]
    Business-Tests [4 Certification Exam(s) ]
    CA-Technologies [21 Certification Exam(s) ]
    Certification-Board [10 Certification Exam(s) ]
    Certiport [3 Certification Exam(s) ]
    CheckPoint [41 Certification Exam(s) ]
    CIDQ [1 Certification Exam(s) ]
    CIPS [4 Certification Exam(s) ]
    Cisco [318 Certification Exam(s) ]
    Citrix [48 Certification Exam(s) ]
    CIW [18 Certification Exam(s) ]
    Cloudera [10 Certification Exam(s) ]
    Cognos [19 Certification Exam(s) ]
    College-Board [2 Certification Exam(s) ]
    CompTIA [76 Certification Exam(s) ]
    ComputerAssociates [6 Certification Exam(s) ]
    Consultant [2 Certification Exam(s) ]
    Counselor [4 Certification Exam(s) ]
    CPP-Institue [2 Certification Exam(s) ]
    CPP-Institute [1 Certification Exam(s) ]
    CSP [1 Certification Exam(s) ]
    CWNA [1 Certification Exam(s) ]
    CWNP [13 Certification Exam(s) ]
    Dassault [2 Certification Exam(s) ]
    DELL [9 Certification Exam(s) ]
    DMI [1 Certification Exam(s) ]
    DRI [1 Certification Exam(s) ]
    ECCouncil [21 Certification Exam(s) ]
    ECDL [1 Certification Exam(s) ]
    EMC [129 Certification Exam(s) ]
    Enterasys [13 Certification Exam(s) ]
    Ericsson [5 Certification Exam(s) ]
    ESPA [1 Certification Exam(s) ]
    Esri [2 Certification Exam(s) ]
    ExamExpress [15 Certification Exam(s) ]
    Exin [40 Certification Exam(s) ]
    ExtremeNetworks [3 Certification Exam(s) ]
    F5-Networks [20 Certification Exam(s) ]
    FCTC [2 Certification Exam(s) ]
    Filemaker [9 Certification Exam(s) ]
    Financial [36 Certification Exam(s) ]
    Food [4 Certification Exam(s) ]
    Fortinet [13 Certification Exam(s) ]
    Foundry [6 Certification Exam(s) ]
    FSMTB [1 Certification Exam(s) ]
    Fujitsu [2 Certification Exam(s) ]
    GAQM [9 Certification Exam(s) ]
    Genesys [4 Certification Exam(s) ]
    GIAC [15 Certification Exam(s) ]
    Google [4 Certification Exam(s) ]
    GuidanceSoftware [2 Certification Exam(s) ]
    H3C [1 Certification Exam(s) ]
    HDI [9 Certification Exam(s) ]
    Healthcare [3 Certification Exam(s) ]
    HIPAA [2 Certification Exam(s) ]
    Hitachi [30 Certification Exam(s) ]
    Hortonworks [4 Certification Exam(s) ]
    Hospitality [2 Certification Exam(s) ]
    HP [750 Certification Exam(s) ]
    HR [4 Certification Exam(s) ]
    HRCI [1 Certification Exam(s) ]
    Huawei [21 Certification Exam(s) ]
    Hyperion [10 Certification Exam(s) ]
    IAAP [1 Certification Exam(s) ]
    IAHCSMM [1 Certification Exam(s) ]
    IBM [1532 Certification Exam(s) ]
    IBQH [1 Certification Exam(s) ]
    ICAI [1 Certification Exam(s) ]
    ICDL [6 Certification Exam(s) ]
    IEEE [1 Certification Exam(s) ]
    IELTS [1 Certification Exam(s) ]
    IFPUG [1 Certification Exam(s) ]
    IIA [3 Certification Exam(s) ]
    IIBA [2 Certification Exam(s) ]
    IISFA [1 Certification Exam(s) ]
    Intel [2 Certification Exam(s) ]
    IQN [1 Certification Exam(s) ]
    IRS [1 Certification Exam(s) ]
    ISA [1 Certification Exam(s) ]
    ISACA [4 Certification Exam(s) ]
    ISC2 [6 Certification Exam(s) ]
    ISEB [24 Certification Exam(s) ]
    Isilon [4 Certification Exam(s) ]
    ISM [6 Certification Exam(s) ]
    iSQI [7 Certification Exam(s) ]
    ITEC [1 Certification Exam(s) ]
    Juniper [64 Certification Exam(s) ]
    LEED [1 Certification Exam(s) ]
    Legato [5 Certification Exam(s) ]
    Liferay [1 Certification Exam(s) ]
    Logical-Operations [1 Certification Exam(s) ]
    Lotus [66 Certification Exam(s) ]
    LPI [24 Certification Exam(s) ]
    LSI [3 Certification Exam(s) ]
    Magento [3 Certification Exam(s) ]
    Maintenance [2 Certification Exam(s) ]
    McAfee [8 Certification Exam(s) ]
    McData [3 Certification Exam(s) ]
    Medical [69 Certification Exam(s) ]
    Microsoft [374 Certification Exam(s) ]
    Mile2 [3 Certification Exam(s) ]
    Military [1 Certification Exam(s) ]
    Misc [1 Certification Exam(s) ]
    Motorola [7 Certification Exam(s) ]
    mySQL [4 Certification Exam(s) ]
    NBSTSA [1 Certification Exam(s) ]
    NCEES [2 Certification Exam(s) ]
    NCIDQ [1 Certification Exam(s) ]
    NCLEX [2 Certification Exam(s) ]
    Network-General [12 Certification Exam(s) ]
    NetworkAppliance [39 Certification Exam(s) ]
    NI [1 Certification Exam(s) ]
    NIELIT [1 Certification Exam(s) ]
    Nokia [6 Certification Exam(s) ]
    Nortel [130 Certification Exam(s) ]
    Novell [37 Certification Exam(s) ]
    OMG [10 Certification Exam(s) ]
    Oracle [279 Certification Exam(s) ]
    P&C [2 Certification Exam(s) ]
    Palo-Alto [4 Certification Exam(s) ]
    PARCC [1 Certification Exam(s) ]
    PayPal [1 Certification Exam(s) ]
    Pegasystems [12 Certification Exam(s) ]
    PEOPLECERT [4 Certification Exam(s) ]
    PMI [15 Certification Exam(s) ]
    Polycom [2 Certification Exam(s) ]
    PostgreSQL-CE [1 Certification Exam(s) ]
    Prince2 [6 Certification Exam(s) ]
    PRMIA [1 Certification Exam(s) ]
    PsychCorp [1 Certification Exam(s) ]
    PTCB [2 Certification Exam(s) ]
    QAI [1 Certification Exam(s) ]
    QlikView [1 Certification Exam(s) ]
    Quality-Assurance [7 Certification Exam(s) ]
    RACC [1 Certification Exam(s) ]
    Real-Estate [1 Certification Exam(s) ]
    RedHat [8 Certification Exam(s) ]
    RES [5 Certification Exam(s) ]
    Riverbed [8 Certification Exam(s) ]
    RSA [15 Certification Exam(s) ]
    Sair [8 Certification Exam(s) ]
    Salesforce [5 Certification Exam(s) ]
    SANS [1 Certification Exam(s) ]
    SAP [98 Certification Exam(s) ]
    SASInstitute [15 Certification Exam(s) ]
    SAT [1 Certification Exam(s) ]
    SCO [10 Certification Exam(s) ]
    SCP [6 Certification Exam(s) ]
    SDI [3 Certification Exam(s) ]
    See-Beyond [1 Certification Exam(s) ]
    Siemens [1 Certification Exam(s) ]
    Snia [7 Certification Exam(s) ]
    SOA [15 Certification Exam(s) ]
    Social-Work-Board [4 Certification Exam(s) ]
    SpringSource [1 Certification Exam(s) ]
    SUN [63 Certification Exam(s) ]
    SUSE [1 Certification Exam(s) ]
    Sybase [17 Certification Exam(s) ]
    Symantec [134 Certification Exam(s) ]
    Teacher-Certification [4 Certification Exam(s) ]
    The-Open-Group [8 Certification Exam(s) ]
    TIA [3 Certification Exam(s) ]
    Tibco [18 Certification Exam(s) ]
    Trainers [3 Certification Exam(s) ]
    Trend [1 Certification Exam(s) ]
    TruSecure [1 Certification Exam(s) ]
    USMLE [1 Certification Exam(s) ]
    VCE [6 Certification Exam(s) ]
    Veeam [2 Certification Exam(s) ]
    Veritas [33 Certification Exam(s) ]
    Vmware [58 Certification Exam(s) ]
    Wonderlic [2 Certification Exam(s) ]
    Worldatwork [2 Certification Exam(s) ]
    XML-Master [3 Certification Exam(s) ]
    Zend [6 Certification Exam(s) ]

    References :

    Dropmark :
    Wordpress :
    Dropmark-Text :
    Blogspot :
    RSS Feed : :

    Back to Main Page | |